Trius Therapeutics, Inc. (Nasdaq:TSRX) announced the dosing of the first patient in a second global Phase 3 pivotal trial in acute bacterial skin and skin structure infections (ABSSSI). The trial, designated TR701-113, is testing tedizolid phosphate (formerly known as torezolid phosphate) administered initially as a once-daily intravenous (IV) infusion with the possibility to switch to once-daily oral therapy in ABSSSI patients. The 113 study is the first clinical trial conducted in collaboration with Bayer HealthCare and, as a result, will recruit patients in North and South America, Europe, South Africa and Asia. The dosing of the first patient in the 113 study triggers a milestone payment to Trius under its collaboration agreement with Bayer.

Read full article and disclaimer at: http://crwewallstreet.com/?p=21661